Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges

Abstract Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a...

Full description

Bibliographic Details
Main Authors: Arash Aghajani Nargesi, Lilach O. Lerman, Alfonso Eirin
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Stem Cell Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13287-017-0727-7
_version_ 1818339736654184448
author Arash Aghajani Nargesi
Lilach O. Lerman
Alfonso Eirin
author_facet Arash Aghajani Nargesi
Lilach O. Lerman
Alfonso Eirin
author_sort Arash Aghajani Nargesi
collection DOAJ
description Abstract Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.
first_indexed 2024-12-13T15:31:45Z
format Article
id doaj.art-48da401353374a61b3a245c61a364113
institution Directory Open Access Journal
issn 1757-6512
language English
last_indexed 2024-12-13T15:31:45Z
publishDate 2017-12-01
publisher BMC
record_format Article
series Stem Cell Research & Therapy
spelling doaj.art-48da401353374a61b3a245c61a3641132022-12-21T23:40:09ZengBMCStem Cell Research & Therapy1757-65122017-12-018111210.1186/s13287-017-0727-7Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challengesArash Aghajani Nargesi0Lilach O. Lerman1Alfonso Eirin2Division of Nephrology and Hypertension, Mayo ClinicDivision of Nephrology and Hypertension, Mayo ClinicDivision of Nephrology and Hypertension, Mayo ClinicAbstract Novel therapies are urgently needed to address the rising incidence and prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD). Mesenchymal stem/stromal cells (MSCs) have shown promising results in experimental AKI and CKD, and have been used in the clinic for more than a decade with an excellent safety profile. The regenerative effects of MSCs do not rely on their differentiation and ability to replace damaged tissues, but are primarily mediated by the paracrine release of factors, including extracellular vesicles (EVs), composed of microvesicles and exosomes. MSC-derived EVs contain genetic and protein material that upon transferring to recipient cells can activate several repair mechanisms to ameliorate renal injury. Recent studies have shown that MSC-derived EV therapy improved renal outcomes in several animal models of AKI and CKD, including ischemia-reperfusion injury, drug/toxin-induced nephropathy, renovascular disease, ureteral obstruction, and subtotal nephrectomy. However, data about the renoprotective effects of EV therapy in patients with renal failure are scarce. This review summarizes current knowledge of MSC-derived EV therapy in experimental AKI and CKD, and discusses the challenges that need to be addressed in order to consider MSC-derived EVs as a realistic clinical tool to treat patients with these conditions.http://link.springer.com/article/10.1186/s13287-017-0727-7Mesenchymal stem cellsExtracellular vesiclesMicrovesiclesExosomesKidney
spellingShingle Arash Aghajani Nargesi
Lilach O. Lerman
Alfonso Eirin
Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges
Stem Cell Research & Therapy
Mesenchymal stem cells
Extracellular vesicles
Microvesicles
Exosomes
Kidney
title Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges
title_full Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges
title_fullStr Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges
title_full_unstemmed Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges
title_short Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges
title_sort mesenchymal stem cell derived extracellular vesicles for kidney repair current status and looming challenges
topic Mesenchymal stem cells
Extracellular vesicles
Microvesicles
Exosomes
Kidney
url http://link.springer.com/article/10.1186/s13287-017-0727-7
work_keys_str_mv AT arashaghajaninargesi mesenchymalstemcellderivedextracellularvesiclesforkidneyrepaircurrentstatusandloomingchallenges
AT lilacholerman mesenchymalstemcellderivedextracellularvesiclesforkidneyrepaircurrentstatusandloomingchallenges
AT alfonsoeirin mesenchymalstemcellderivedextracellularvesiclesforkidneyrepaircurrentstatusandloomingchallenges